OCS — Oculis Holding AG
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1953530 ·
Last close
$13.18
Market Cap
$731.86M
52W High
$30.69
52W Low
$10.52
ADV30
272,958
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -23,568,000 | -9,970,000 | 250,335,000 | 61,614,000 | 30,998,000 |
| Mar 2026 | 0 | — | -21,728,000 | -28,852,000 | 243,993,000 | 64,564,000 | 47,345,000 |
| Dec 2025 | 0 | — | -20,633,000 | -23,514,000 | 235,963,000 | 81,329,000 | 39,893,000 |
| Sep 2025 | 0 | — | -20,296,000 | -16,855,000 | 167,836,000 | 46,440,000 | 37,242,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-62,678,000
Investing CF
$-34,945,000
Financing CF
$106,690,000
CapEx
$-295,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-1.72
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-413,366,000
Inventory
—
Receivables
$1,576,000
ST Investments
$157,470,000
EBIT TTM
$-94,128,000
Pretax Income TTM
$-94,887,000
Interest Exp TTM
$759,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,173,000
EBITDA
$-85,977,000
Free Cash Flow
$-41,372,752
Enterprise Value
$581,983,040
Total Cash
$228,324,000
Total Debt
$2,543,000
Shares Out
55,527,961
Trailing EPS
$-1.73
Book Value
$4.43
ROE
-43.7%
ROA
-25.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -81,672,000 | -98,957,000 | 235,963,000 | 39,893,000 | — | -66,304,000 |
| Dec 2024 | 0 | -73,204,000 | -85,777,000 | 120,353,000 | 46,970,000 | — | -48,919,000 |
| Dec 2023 | 0 | -45,851,000 | -88,802,000 | 114,353,000 | 20,625,000 | — | -55,037,000 |
| Dec 2022 | 0 | -32,376,000 | -38,698,000 | 37,060,000 | 135,051,000 | — | -25,074,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.05
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $15.00 · spot: $13.18 · call volume: 34 · put volume: 20Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $732.79M | $9.14 | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $743.94M | $35.31 | — |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $718.32M | $35.28 | — |
| CTMX | CytomX Therapeutics, Inc. | $716.89M | $3.29 | — |
| MNPR | Monopar Therapeutics | $747.47M | $111.36 | — |
News headlines (Yahoo Finance, 1h cache)
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
2026-08-24 08:00 · Yahoo
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
2026-08-14 20:05 · Yahoo
Oculis to Buy Accure's Global Development, Commercial Rights to Privosegtor
2026-08-10 08:45 · Yahoo
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
2026-08-10 07:30 · Yahoo
Oculis Reports Q2 2026 Financial Results and Provides Company Update
2026-08-06 20:05 · Yahoo
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
2026-07-02 08:00 · Yahoo
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
2026-06-11 08:00 · Yahoo
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
2026-06-09 08:00 · Yahoo
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
2026-06-08 19:25 · Yahoo
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?
2026-08-14 13:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.